Medical Oncologist
CION Cancer Clinics
Immunotherapy after a liver transplant: why it is usually avoided | CION Cancer Clinics
Immunotherapy is usually avoided after a liver transplant because it can trigger rejection of the new liver. It works by switching the immune system up, while anti-rejection medicine keeps it switched down. This page explains why the risk is taken so seriously, what is offered instead if liver cancer returns, and why the caution does not apply to people who still have their own liver. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
MM
Medically reviewed by Dr. Muralidhar MuddusettyConsultant Surgical Oncologist · MBBS (AIIMS), MS (Surgery, AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Can I have immunotherapy after a liver transplant?
- Why does immunotherapy put a transplanted liver at risk?
- What happens if liver cancer comes back after a transplant?
- What are the options instead of immunotherapy?
- Does this caution apply to everyone with liver cancer?
- What this page cannot tell you
- Common questions about immunotherapy after a liver transplant
The short answer
Can I have immunotherapy after a liver transplant?
Usually not. Immunotherapy works by releasing the brakes on the immune system, and after a transplant those brakes are what stop your body attacking the new liver. Taking the brakes off can trigger rejection, which can be sudden, severe and sometimes impossible to reverse.
This page is for people whose liver cancer, usually hepatocellular carcinoma (HCC), has come back after a liver transplant, and for families who have read that immunotherapy is now the first choice for liver cancer and want to know why it is not being offered. That first-choice advice was built on people who still had their own liver. It does not carry over to someone living with a donated one.
Why this question comes up
Combinations such as atezolizumab with bevacizumab, or durvalumab with tremelimumab, are now widely used for advanced liver cancer. It is natural to ask why the newest treatment is off the table. The answer is not that your case matters less. It is that the same drug that helps one person can put another person's transplanted liver at real risk.
Never start, stop or change anti-rejection medicine on your own. Any change is made only by the transplant team.How the risk arises
Why does immunotherapy put a transplanted liver at risk?
A transplant and immunotherapy pull the immune system in opposite directions. Understanding that tug makes the decision easier to accept.
The new liver is seen as foreign
Your immune system recognises the donated liver as not your own. Left alone, it would attack it. That is why everyone who has a transplant takes anti-rejection medicine, called immunosuppression, for life.
Immunotherapy removes a safety catch
Checkpoint drugs block signals such as PD-1 and PD-L1 that calm the immune system down. Those same signals help the body tolerate the new liver. Blocking them can wake the attack the transplant medicines were holding back.
Rejection can be hard to undo
When rejection follows immunotherapy, it can move quickly and may not respond to the usual rescue treatment. Losing the new liver is a life-threatening event.
Signs the team watches for
- Rising liver blood tests
- New yellowing of the eyes or skin
- Fever, tiredness or pain over the liver
The evidence is thin
Transplant patients were left out of the main trials. What doctors know comes from individual case reports and small collections of cases, which is why most teams treat the risk with great caution.
Not sure whether this applies to you?
Ask an oncologistStep by step
What happens if liver cancer comes back after a transplant?
The return is confirmed
A rising AFP (a blood marker some liver cancers make) or a new spot on a follow-up scan leads to further imaging, and sometimes a biopsy. CION arranges these through diagnostic partners. More is on our page on cancer coming back after a transplant.
Both teams review it together
The tumour board and the transplant team look at where the cancer is, how many spots there are and how the new liver is working. Neither team should decide alone.
The anti-rejection plan is reviewed
Some transplant teams adjust or switch the anti-rejection medicine when cancer returns. This is their decision, made with the oncologist, and never something to change at home.
A treatment is chosen
Options include treating a few spots directly, or tablets such as sorafenib or lenvatinib. Supportive and symptom care runs alongside whatever is chosen.
Side by side
What are the options instead of immunotherapy?
Option
When it may be considered
Surgery to remove a single returning spot
One or a few spots, in a place that can be reached safely, in someone fit for an operation
Ablation or focused radiation such as SBRT
A small number of spots in the liver, lungs or bones, coordinated through partner hospitals
Tablets such as sorafenib or lenvatinib
Cancer in several places, where a whole-body treatment is needed
Immunotherapy
Generally avoided, and considered only rarely, after a long and frank talk with the transplant team
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Did you know
The rejection risk also matters before a transplant. If you have immunotherapy while waiting for a new liver, the transplant team will want to know exactly when the last dose was given, so tell them every cancer medicine you have had.
Who this is not about
Does this caution apply to everyone with liver cancer?
No. If you still have your own liver, this caution does not apply to you. For most people with advanced HCC who have not had a transplant, immunotherapy combinations are a standard and often preferred choice, as our page on immunotherapy for liver cancer explains.
Other transplants raise the same question
People with a kidney, heart or other organ transplant who develop any cancer face a similar trade-off. The detail differs by organ, so the decision is made with that specific transplant team.
When immunotherapy is very rarely discussed
Occasionally, when nothing else is left and the person fully understands that the new liver could be lost, a team may discuss it. This is an exceptional conversation, not a routine offer. Many people decide that keeping the transplant matters more, and that is a reasonable choice.
Choosing not to take a risk with the new liver is not giving up. It is a decision about what matters most.Being straight with you
What this page cannot tell you
It cannot tell you whether your cancer can be treated directly, which tablet suits you, or whether your anti-rejection medicine should change. Those answers depend on your scans, your new liver's blood tests and your transplant history, read together.
Who to ask
Your transplant hepatologist manages the new liver and the anti-rejection medicine. CION's medical and surgical oncologists can review the cancer, present it to the tumour board and plan treatment in step with the transplant team. CION does not carry out transplants; these take place at licensed transplant centres.
Bring the full story
Bring your transplant discharge summary, the latest anti-rejection prescription, recent liver tests and every scan since the operation. It saves time and avoids repeated tests. If you are travelling from a district, ask whether some blood tests can be done closer to home.
See our page on rejection signs and what is done if you are unsure what to watch for.Questions we are asked
Common questions about immunotherapy after a liver transplant
Why is immunotherapy avoided after a liver transplant?
Because it switches the immune system up, while anti-rejection medicine is switching it down to protect the new liver. Immunotherapy can tip the balance and cause rejection, which may be severe and may not reverse. For most people the risk outweighs the likely benefit.
Is rejection certain if I take immunotherapy?
No, it does not happen to everyone, but it is common enough and serious enough that most teams avoid these drugs. The evidence comes from case reports rather than trials, so nobody can predict reliably who will reject and who will not.
What treatment is offered instead?
It depends on where the cancer has returned. A few spots may be removed, ablated or treated with focused radiation. Cancer in several places is usually treated with tablets such as sorafenib or lenvatinib. Our page on choosing between sorafenib and lenvatinib explains that choice.
Can tablets such as sorafenib be taken with anti-rejection medicine?
They are used after transplant, but they can affect the levels of some anti-rejection medicines in the blood. The transplant team usually checks those levels more often when a new cancer medicine starts. Always tell both teams about every medicine you take.
Can my anti-rejection medicine be reduced to fight the cancer?
Some transplant teams lower or switch anti-rejection medicine when cancer returns, because a strongly suppressed immune system may let cancer grow more easily. It is a careful balance against rejection, and only the transplant team should make that change.
I had immunotherapy before my transplant. Is that a problem?
It may be. Some people receive immunotherapy to shrink cancer while waiting for a new liver. The transplant team needs to know exactly when the last dose was given, because recent immunotherapy can raise the risk of early rejection.
What signs of rejection should my family watch for?
New yellowing of the eyes or skin, fever, dark urine, pale stools, unusual tiredness or pain under the right ribs. Often rejection shows first on blood tests, before any symptom. Contact the transplant team the same day if any of these appear.
Can CION review my case if I had my transplant elsewhere?
Yes. Bring your transplant records and recent scans, and a CION oncologist will review the cancer and work alongside your transplant team. Call the CION helpline to arrange a consultation or a second opinion.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Immunotherapy for Liver Cancer
- National Cancer Institute — Immunotherapy for Cancer
- NIDDK — Liver Transplant - NIDDK
- MedlinePlus — Liver Transplantation
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Has the cancer come back after a transplant?
A CION oncologist can review your scans and work alongside your transplant team to plan the next step. One helpline serves every CION centre.